AYAnita Yang

Anita Yang

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anita Yang has a total of 29 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of Clinical Pharmacist Integration on Weight Management and Transplant Eligibility Among Patients With End‐Stage Kidney Disease With Obesity

    by Anita Yang, Dominic Tecza, Carly Medwin, Mary Chandran

    Background: Obesity is a barrier to kidney transplantation in patients with end‐stage kidney disease (ESKD). Injectable incretin peptides (IIP) have transformed weight management; however, real‐world data in ESKD are limited. This study evaluated the impact of integrating a clinical pharmacist practitioner (CPP) into an interprofessional high body mass index (BMI) kidney transplant clinic on weight loss and transplant eligibility outcomes. Methods: This single‐center, retrospective study included adults with ESKD and obesity‐prescribed IIP for transplant eligibility between June, 2022 and December, 2024. Cohort 1 included patients treated before CPP implementation; Cohort 2 included patients following implementation. The primary outcome was the percent change in body mass index (BMI) at 3, 6, and 12 months following IIP initiation. Secondary outcomes included changes in transplant eligibility status, IIP dose intensity, and predefined adverse events (AEs) at 12 months. Results: Eighty‐four patients were included (Cohort 1: n = 28; Cohort 2: n = 56). Cohort 2 achieved greater BMI reductions at 3 (−2.0% vs. +1.45%), 6 (−3.3% vs. +1.16%), and 12 months (−8.0% vs. +2.8%; p < 0.01 for all). Among patients initially ineligible for kidney transplantation, 45% of patients in Cohort 2 became active on the transplant waitlist by 12 months compared with 11.5% in Cohort 1 ( p = 0.006). More patients in Cohort 2 reached high IIP dose intensity (48.2% vs. 3.6%, p < 0.001), without differences in AE. Conclusions: IIP therapy appears safe and effective in ESKD. CPP integration was associated with greater weight loss, increased achievement of active transplant eligibility, and improved treatment optimization, highlighting its potential role in addressing obesity‐related barriers to transplantation.

  • Impact of Glucagon‐Like Peptide‐1 Receptor Agonists on Proteinuria in Kidney Transplant Recipients

    by Stephanie Shabanowitz, Ryan Clark, Rachel Bassett Allen, Mary Chandran, Anita Yang

    Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have shown significant cardiorenal benefits in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM). However, the impact of GLP‐1 RAs on cardiorenal outcomes in kidney transplant recipients (KTRs) remains unclear. This study aims to assess the effect of GLP‐1 RA therapy on proteinuria and metabolic parameters in KTRs, with and without T2DM, 12 months following GLP‐1 RA initiation. Methods: A single‐center, retrospective study was conducted to evaluate the safety and efficacy of GLP‐1 RAs in adult KTRs from June 1, 2022 to December 31, 2023. Primary outcomes were changes in urine protein‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1, 3, 6, and 12 months after initiation of GLP‐1 RAs. Secondary outcomes assessed changes in estimated glomerular filtration (eGFR), body mass index (BMI), and hemoglobin A1c (A1C). Safety outcomes included cardiovascular hospitalizations, acute kidney injury, pancreatitis, and biopsy‐proven rejection within 12 months. Results: Forty KTRs received GLP‐1 RA therapy with a mean time to initiation of 4.3 months post‐transplant, and the majority of patients had T2DM (87.5%). Baseline UPCR and UACR were 0.86 and 669 mg/g, respectively. UPCR at 1, 3, and 6 months post‐initiation was 0.38 g/g, 0.37 g/g, and 0.30 g/g, respectively. UACR at 1, 3, and 6 months post‐initiation was 313 mg/g, 285 mg/g, and 234 mg/g, respectively. A 55% decrease from baseline in UPCR and UACR was observed at 1 month ( p = 0.070) and a 50% decrease from baseline was observed at 12 months ( p = 0.058), achieving UPCR of 0.43 g/g and UACR of 320 mg/g. A1C, eGFR, and BMI remained stable. Minimal safety events occurred. Conclusion: GLP‐1 RAs demonstrated clinically significant improvements in proteinuria as early as 1 month post‐initiation in KTRs. Proteinuria significantly improved from severely increased to moderately increased at 6 months following GLP‐1 RAs, with good tolerability. GLP‐1 RAs may offer renal benefits in KTRs with T2DM without compromising allograft function. Future studies should include closer monitoring of KTRs on immunosuppression with high gastrointestinal adverse effect profiles, and larger studies are needed to assess the long‐term impact of GLP‐1 RAs in KTRs irrespective of T2DM.

  • Open Access

    Assessing Primary Aldosteronism Screening Implementation and Interpretation in an Outpatient Internal Medicine Clinic: A Cohort Study

    by Rachel B. Allen, Thomas Hui, Shelby Tungate Lopez, Anne M. Komé, Anita Yang, Lindsay Zink, Luis Borges Espinosa

  • Impact of Sodium‐Glucose Cotransporter‐2 Inhibitors on Proteinuria in Kidney Transplant Recipients

    by Emili Anderson, Stephanie Shabanowitz, Kinley Jessup, Rachel Bassett Allen, Mary Chandran, Anita Yang

    Introduction: Proteinuria is a marker of kidney dysfunction and increased cardiovascular mortality. Sodium‐glucose cotransporter 2 inhibitors (SGLT2i) have demonstrated cardiorenal protection in chronic kidney disease, regardless of type 2 diabetes mellitus (T2DM) status. However, data evaluating SGLT2i impact on cardiorenal outcomes in kidney transplant recipients (KTRs) are limited. Methods: This single‐center, retrospective cohort study evaluated the safety and efficacy of SGLT2i therapy in adult KTRs transplanted between January 1, 2020 and December 31, 2023. Primary outcomes were changes in urine protein‐to‐creatinine ratio (UPCR) and urine albumin‐to‐creatinine ratio (UACR) at 1‐, 3‐, 6‐, and 12‐months post‐initiation. Secondary outcomes included changes in estimated glomerular filtration rate (eGFR), BMI, and hemoglobin A1c (HbA1c). Safety outcomes were cardiovascular hospitalization, acute kidney injury, urinary tract infection, and biopsy‐proven rejection within 12 months. Results: SGLT2i therapy was initiated in 77 KTRs, 524 days post‐transplant, predominantly in males (74.3%), African Americans (62.8%), and patients with T2DM (80.7%). Baseline UPCR and UACR were 0.387 g/g and 302.2 mg/g, respectively. No significant changes in UPCR, UACR, or eGFR were observed. Renal function was preserved at 12 months, with a transient decline at 1‐month that returned to baseline by 3 months. HbA1c and BMI remained stable. Few safety events occurred. Conclusions: In KTRs with moderate proteinuria, SGLT2i therapy was well tolerated with stable renal function over 12 months. A transient eGFR dip is consistent with patterns seen in non‐transplant populations. Absence of significant metabolic changes may reflect well‐controlled baseline parameters. Further studies are warranted to evaluate SGLT2i benefits in KTRs, especially in patients with higher grade proteinuria or early post‐transplant initiation.


  • Open Access

    Diabetes Educators: Understanding the Role of Finerenone in Chronic Kidney Disease Associated with Type 2 Diabetes Mellitus

    by Anne M. Komé, Anita Yang, Patrick Gee, Klara R. Klein

    People living with type 2 diabetes mellitus (T2DM) are at risk of developing diabetes-related complications such as chronic kidney disease (CKD). Screening for CKD is considered the standard of diabetes care, but less than half of people living with diabetes in the United States receive guideline-directed kidney disease testing. Despite recent pharmacologic advances for the treatment of this condition, insufficient screening delays both diagnosis and treatment of diabetes-related CKD and increases the risk of poor outcomes. The nonsteroidal mineralocorticoid receptor antagonist finerenone is an orally administered drug that, when taken with the maximum tolerated dose of a renin–angiotensin–aldosterone system inhibitor, can provide kidney and cardiovascular benefits for people living with T2DM-related CKD. Yet, uptake of this drug has been slow. Increasing awareness of finerenone may encourage its use in clinical practice. Diabetes educators are healthcare professionals (HCPs) with extensive diabetes care experience who encourage diabetes self-management and provide patients with education on the prevention of diabetes-related complications. Diabetes educators bridge knowledge and care gaps among other HCPs by facilitating communication between members of the care team and raising awareness on the importance of CKD prevention and screening. Additionally, diabetes educators reinforce the clinical evidence behind available treatments to promote adherence to guidelines. Here, the evidence for finerenone in T2DM-related CKD and the role of the diabetes educator from both patient and HCP perspectives are reviewed. Graphical abstract available for this article. Graphical Abstract


  • Pharmacist‐led dosing reduces tacrolimus intrapatient variability in lung transplant recipients

    by Anita Yang, Roxanne McKnight, Alyson Prom, Megan Byrne, Rickey A. Evans, Christina T. Doligalski


  • Poor tolerability of cystic fibrosis transmembrane conductance regulator modulator therapy in lung transplant recipients

    by Christina Teeter Doligalski, Cameron J. McKinzie, Anita Yang, L. Jason Lobo, Raymond Coakley

    Elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) is a highly effective therapy for patients with cystic fibrosis (CF) with potential benefits in lung transplant recipients (LTRs) for extrapulmonary CF manifestations; however, tolerability and efficacy in this population are largely unknown. We report our experience with ELX/TEZ/IVA in LTRs for extrapulmonary complications of CF including tolerability, drug–drug interactions, and therapeutic benefit. All LTRs at a single center initiated on ELX/TEZ/IVA were reviewed. Adverse events and patient‐reported outcomes attributed to ELX/TEZ/IVA were documented. Pulmonary function, tacrolimus requirements in mg/kg/dl, body mass index (BMI), and reason for initiation were assessed at the initiation of ELX/TEZ/IVA, and at 12 months post‐initiation or at the time of discontinuation for those in whom therapy was discontinued. Thirteen LTRs were initiated on ELX/TEZ/IVA at a mean of 115 ± 92 months post‐transplant. All were initiated on ELX/TEZ/IVA for sinus or sinus and gastrointestinal CF manifestations. Five (38.4%) patients discontinued therapy due to declining pulmonary function (2/5, 40%), mood disturbances (2/5, 40%), or lack of benefit (1/5, 20%). Of the eight patients who remain on ELX/TEZ/IVA, four reported adverse effects and three LTRs temporarily held therapy. Six (46.2%) LTRs reported improvement in sinus symptoms, while four (30.7%) reported improved gastrointestinal symptoms. Weight declined in the cohort overall. Tacrolimus dose requirements decreased following initiation of ELX/TEZ/IVA therapy, with a 50% decline in dose requirements observed. In our experience, ELX/TEZ/IVA in LTRs is poorly tolerated with modest perceived extrapulmonary benefit and a significant effect on tacrolimus dose requirements. More data are needed to determine the benefits of ELX/TEZ/IVA therapy in LTRs.